Stay Ahead of the Game With Oxford Industries (OXM) Q1 Earnings: Wall Street's Insights on Key Metrics

Analysts anticipate Oxford Industries' (OXM) upcoming earnings report will reveal a 31.6% year-over-year decline in quarterly EPS to $1.82, with revenues expected to decrease by 3.3% to $385.23 million. Consensus EPS estimates have been revised downward by 2% in the past month, and while 'Net Sales' are expected to increase for Emerging Brands (+2.1%) and Lilly Pulitzer (+3.1%), declines are projected for Tommy Bahama (-5%) and Johnny Was (-10%). Oxford Industries shares have underperformed the S&P 500 over the past month, and the stock is anticipated to perform in line with the market in the near term, according to its Zacks Rank #3 (Hold).

Analysis

Oxford Industries (OXM) is poised to report a significant downturn in its upcoming quarterly results, with analysts forecasting earnings per share of $1.82, a 31.6% decline year-over-year, and revenues of $385.23 million, down 3.3% from the prior year. This outlook is further tempered by a 2% downward revision in the consensus EPS estimate over the past 30 days, a factor often correlated with short-term stock price movements. The anticipated revenue performance is mixed across its brand portfolio: 'Net Sales-Emerging Brands' are expected to grow by 2.1% to $33.70 million and 'Net Sales-Lilly Pulitzer' by 3.1% to $91.10 million. Conversely, significant declines are projected for its larger brands, with 'Net Sales-Tommy Bahama' expected to fall by 5% to $214.30 million and 'Net Sales-Johnny Was' by a substantial 10% to $46.10 million. Reflecting these headwinds and a moderately negative sentiment (score -0.6), OXM shares have underperformed, returning -1.4% over the past month compared to the S&P 500 composite's +5.3% gain. The stock currently holds a Zacks Rank #3 (Hold), suggesting its performance will likely mirror the broader market in the near term.

Key Decisions for Investors

• Investors should approach Oxford Industries with caution ahead of its earnings release, given the anticipated significant decline in EPS and overall revenue, alongside recent downward estimate revisions.
• Careful monitoring of individual brand performance is warranted, particularly the contrasting growth in Emerging Brands and Lilly Pulitzer against the projected sharp declines in Tommy Bahama and Johnny Was, to assess the portfolio's overall health.
• Considering the stock's recent underperformance and the Zacks Rank #3 (Hold), maintaining current positions or waiting for clearer post-earnings signals might be prudent before making significant allocation changes.